197 related articles for article (PubMed ID: 14962821)
1. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
[TBL] [Abstract][Full Text] [Related]
2. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T;
Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776
[TBL] [Abstract][Full Text] [Related]
3. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
[TBL] [Abstract][Full Text] [Related]
4. Rifapentine for the treatment of tuberculosis: is it all it can be?
Gordin FM
Am J Respir Crit Care Med; 2004 Jun; 169(11):1176-7. PubMed ID: 15161608
[No Abstract] [Full Text] [Related]
5. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of rifapentine in children.
Blake MJ; Abdel-Rahman SM; Jacobs RF; Lowery NK; Sterling TR; Kearns GL
Pediatr Infect Dis J; 2006 May; 25(5):405-9. PubMed ID: 16645503
[TBL] [Abstract][Full Text] [Related]
7. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
Bock NN; Sterling TR; Hamilton CD; Pachucki C; Wang YC; Conwell DS; Mosher A; Samuels M; Vernon A;
Am J Respir Crit Care Med; 2002 Jun; 165(11):1526-30. PubMed ID: 12045127
[TBL] [Abstract][Full Text] [Related]
8. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis.
Mitchison DA
Am J Respir Crit Care Med; 2003 May; 167(10):1298-9. PubMed ID: 12738593
[No Abstract] [Full Text] [Related]
9. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
10. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
Dorman SE; Goldberg S; Stout JE; Muzanyi G; Johnson JL; Weiner M; Bozeman L; Heilig CM; Feng PJ; Moro R; Narita M; Nahid P; Ray S; Bates E; Haile B; Nuermberger EL; Vernon A; Schluger NW;
J Infect Dis; 2012 Oct; 206(7):1030-40. PubMed ID: 22850121
[TBL] [Abstract][Full Text] [Related]
11. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
Langdon G; Wilkins JJ; Smith PJ; McIlleron H
Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
[TBL] [Abstract][Full Text] [Related]
12. Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection.
Cruz AT; Starke JR
Pediatr Infect Dis J; 2016 Jul; 35(7):811-3. PubMed ID: 27088582
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.
Langdon G; Wilkins J; McFadyen L; McIlleron H; Smith P; Simonsson US
Antimicrob Agents Chemother; 2005 Nov; 49(11):4429-36. PubMed ID: 16251279
[TBL] [Abstract][Full Text] [Related]
14. Rifapentine: its role in the treatment of tuberculosis.
Temple ME; Nahata MC
Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
[TBL] [Abstract][Full Text] [Related]
15. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
Keung A; Eller MG; McKenzie KA; Weir SJ
Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
[TBL] [Abstract][Full Text] [Related]
16. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
Brooks KM; George JM; Pau AK; Rupert A; Mehaffy C; De P; Dobos KM; Kellogg A; McLaughlin M; McManus M; Alfaro RM; Hadigan C; Kovacs JA; Kumar P
Clin Infect Dis; 2018 Jul; 67(2):193-201. PubMed ID: 29415190
[TBL] [Abstract][Full Text] [Related]
17. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.
Egelund EF; Weiner M; Singh RP; Prihoda TJ; Gelfond JA; Derendorf H; Mac Kenzie WR; Peloquin CA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4904-10. PubMed ID: 24841270
[TBL] [Abstract][Full Text] [Related]
18. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
[TBL] [Abstract][Full Text] [Related]
19. Single-dose pharmacokinetics of rifapentine in women.
Keung AC; Eller MG; Weir SJ
J Pharmacokinet Biopharm; 1998 Feb; 26(1):75-85. PubMed ID: 9773393
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
